These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11333129)

  • 1. Phase II evaluation of bryostatin-1 in metastatic melanoma.
    Bedikian AY; Plager C; Stewart JR; O'Brian CA; Herdman SK; Ross M; Papadopoulos N; Eton O; Ellerhorst J; Smith T
    Melanoma Res; 2001 Apr; 11(2):183-8. PubMed ID: 11333129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized phase II study of two schedules of bryostatin-1 (NSC339555) in patients with advanced malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group study.
    Tozer RG; Burdette-Radoux S; Berlanger K; Davis ML; Lohmann RC; Rusthoven JR; Wainman N; Zee B; Seymour L;
    Invest New Drugs; 2002 Nov; 20(4):407-12. PubMed ID: 12448658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of patients with metastatic melanoma with bryostatin-1--a phase II study.
    Gonzalez R; Ebbinghaus S; Henthorn TK; Miller D; Kraft AS
    Melanoma Res; 1999 Dec; 9(6):599-606. PubMed ID: 10661772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of bryostatin 1 in metastatic malignant melanoma.
    Propper DJ; Macaulay V; O'Byrne KJ; Braybrooke JP; Wilner SM; Ganesan TS; Talbot DC; Harris AL
    Br J Cancer; 1998 Nov; 78(10):1337-41. PubMed ID: 9823975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee.
    Philip PA; Rea D; Thavasu P; Carmichael J; Stuart NS; Rockett H; Talbot DC; Ganesan T; Pettit GR; Balkwill F
    J Natl Cancer Inst; 1993 Nov; 85(22):1812-8. PubMed ID: 8230261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group Study.
    Armstrong DK; Blessing JA; Look KY; Schilder R; Nunez ER
    Invest New Drugs; 2003 Aug; 21(3):373-7. PubMed ID: 14578687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study.
    Haas NB; Smith M; Lewis N; Littman L; Yeslow G; Joshi ID; Murgo A; Bradley J; Gordon R; Wang H; Rogatko A; Hudes GR
    Clin Cancer Res; 2003 Jan; 9(1):109-14. PubMed ID: 12538458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of prolonged infusion Bryostatin-1 in patients with advanced malignancies.
    Marshall JL; Bangalore N; El-Ashry D; Fuxman Y; Johnson M; Norris B; Oberst M; Ness E; Wojtowicz-Praga S; Bhargava P; Rizvi N; Baidas S; Hawkins MJ
    Cancer Biol Ther; 2002; 1(4):409-16. PubMed ID: 12432257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study.
    Weitman S; Langevin AM; Berkow RL; Thomas PJ; Hurwitz CA; Kraft AS; Dubowy RL; Smith DL; Bernstein M
    Clin Cancer Res; 1999 Sep; 5(9):2344-8. PubMed ID: 10499603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
    Cragg LH; Andreeff M; Feldman E; Roberts J; Murgo A; Winning M; Tombes MB; Roboz G; Kramer L; Grant S
    Clin Cancer Res; 2002 Jul; 8(7):2123-33. PubMed ID: 12114412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    Varterasian ML; Mohammad RM; Eilender DS; Hulburd K; Rodriguez DH; Pemberton PA; Pluda JM; Dan MD; Pettit GR; Chen BD; Al-Katib AM
    J Clin Oncol; 1998 Jan; 16(1):56-62. PubMed ID: 9440723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer.
    Zonder JA; Shields AF; Zalupski M; Chaplen R; Heilbrun LK; Arlauskas P; Philip PA
    Clin Cancer Res; 2001 Jan; 7(1):38-42. PubMed ID: 11205915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.
    Jayson GC; Crowther D; Prendiville J; McGown AT; Scheid C; Stern P; Young R; Brenchley P; Chang J; Owens S
    Br J Cancer; 1995 Aug; 72(2):461-8. PubMed ID: 7640233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    Varterasian ML; Mohammad RM; Shurafa MS; Hulburd K; Pemberton PA; Rodriguez DH; Spadoni V; Eilender DS; Murgo A; Wall N; Dan M; Al-Katib AM
    Clin Cancer Res; 2000 Mar; 6(3):825-8. PubMed ID: 10741703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1.
    Szallasi Z; Du L; Levine R; Lewin NE; Nguyen PN; Williams MD; Pettit GR; Blumberg PM
    Cancer Res; 1996 May; 56(9):2105-11. PubMed ID: 8616857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study.
    Armstrong DK; Blessing JA; Rader J; Sorosky JI;
    Invest New Drugs; 2003 Nov; 21(4):453-7. PubMed ID: 14586213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of intravenous bryostatin 1 in patients with advanced cancer.
    Prendiville J; Crowther D; Thatcher N; Woll PJ; Fox BW; McGown A; Testa N; Stern P; McDermott R; Potter M
    Br J Cancer; 1993 Aug; 68(2):418-24. PubMed ID: 8347500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase Ib trial of bryostatin 1 in patients with refractory malignancies.
    Grant S; Roberts J; Poplin E; Tombes MB; Kyle B; Welch D; Carr M; Bear HD
    Clin Cancer Res; 1998 Mar; 4(3):611-8. PubMed ID: 9533528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies.
    Dowlati A; Lazarus HM; Hartman P; Jacobberger JW; Whitacre C; Gerson SL; Ksenich P; Cooper BW; Frisa PS; Gottlieb M; Murgo AJ; Remick SC
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5929-35. PubMed ID: 14676117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of bryostatin 1 in patients with relapsed multiple myeloma.
    Varterasian ML; Pemberton PA; Hulburd K; Rodriguez DH; Murgo A; Al-Katib AM
    Invest New Drugs; 2001; 19(3):245-7. PubMed ID: 11561682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.